• Copyright and Legal Disclaimer

    Please carefully review the following terms and conditions of use, which should be read in conjunction with the terms and other statements you acknowledged when accessing this Web site and apply to everyone who visits this or any other of Mylan’s Web sites. By accessing and using these Web sites, you are agreeing to abide by, and be bound by, the following terms and conditions and any amendments in effect at the time of your visit. Mylan may modify these terms and conditions at any time without notice by updating these legal notices, and we encourage you to review the terms and conditions because any such modifications will be binding on you.

    Copyright/Trademark Notice 
    Trademarks and service marks on this or any other Mylan Web sites are registered and unregistered trademarks of Mylan and others. Nothing contained on the Web sites should be construed as granting any license or right to use any such marks without the written permission of Mylan or such other party who may own such mark(s). The contents of this or any Mylan Web sites (including, without limitation, their arrangement and layout; names and logos; and text, illustrations and artwork) are the copyrighted property of Mylan (or the original creator of the material) and are protected under applicable copyright and trademark laws. Mylan authorizes you, subject to these terms and conditions, to access and use the Mylan Web sites and the copyrighted content solely for personal use, at Mylan’s discretion. Any other use is expressly prohibited. This license is revocable at any time without notice and with or without cause. Any unauthorized use of the trademarks or other contents of any of Mylan’s Web sites may violate civil or criminal laws. You must preserve all copyright, trademarks, service marks, and other proprietary notices contained in the copyrighted content on any copy you make of such content.

    Mylan’s Web sites may contain links to third-party Web sites, which are provided as a convenience to users of our sites. Mylan makes no claim or warranty of, and is not responsible for, any information found in a linked Web site.

    No Representation or Warranty 

    While Mylan uses reasonable efforts to include up-to-date and accurate information on its Web sites, Mylan does not make, and expressly disclaims, any representations or warranties of any kind, either express or implied (including, without limitation, any implied warranties of merchantability, fitness for a particular purpose or non-infringement)with regard to any such information, its accuracy or completeness or the frequency that it is updated. You agree that your use of the Mylan’s Web sites and everything on Mylan’s Web sites is provided on an “AS IS“ and “AS AVAILABLE“ basis. Mylan assumes no liability or responsibility for any errors or omissions in the content of its Web sites. Mylan makes no warranties that (i) the Mylan Web sites will meet your requirements, (ii) the Mylan Web sites will be uninterrupted, timely, secure, or error-free, (iii) the results that may be obtained from the use of the Mylan Web sites will be accurate or reliable, (iv) the quality of any goods or services available on the Mylan Web sites will meet your expectations, (v) any errors on the Mylan Web sites will be corrected, (vi) that your use of the Mylan Web sites or any material obtained from the Mylan Web sites will not damage your computer system or mobile device or that no loss of data will result from obtaining such material.

    Limitation of Liability 
    Your use of Mylan’s Web sites is at your own risk. In no event shall Mylan or any of its officers, directors, employees or affiliates, be liable, directly or indirectly, for any damages of any kind or nature, including, without limitation, direct, special, incidental or consequential, exemplary, or any claims or losses, resulting from or in connection with the creation or use of, or reliance on, this site, any other Mylan Web site or any linked Web site contained in any such sites, or any of the information accessed through any such site or from the inability to use any such site. This limitation includes damage to your computer equipment or any viruses that may infect your computer equipment or other property, loss of profits, goodwill, or other intangible losses (even if Mylan has been advised of the possibility of such damages), resulting from: (i) the use or the inability to use the Mylan Web sites; (ii) the cost of procuring substitute goods and services resulting from any goods, data, information or services obtained or messages received or transactions entered into through, from, or as a result of the Mylan Web sites; (iii) unauthorized access to or alteration of your transmissions or data; (iv) statements or conduct of any user or third party on the Mylan Web sites; (v) your reliance on content made available by Mylan; or (vi) any other matter relating to the Mylan Web sites.

    Some jurisdictions do not allow the exclusion of certain warranties or the limitation or exclusion of liability for incidental or consequential damages. Accordingly, some of the above limitations may not apply to you.

    To the fullest extent possibly by law, Mylan’s and any of its officers, directors, employees or affiliates’ maximum liability arising out of or in connection with the Mylan Web sites or your use of Mylan’s content, regardless of cause of action (whether in contract, tort, breach of warranty, or otherwise), will not exceed $100 in the aggregate.

    You agree to defend, indemnify, and hold harmless Mylan and any of its officers, directors, employees or affiliates from and against any claims, actions, or demands, including without limitation reasonable legal and accounting fees, alleging or resulting from (i) your use of or reliance on any third-party content, (ii) your use of or reliance on any Mylan content, (iii) your misuse of the Mylan Web sites, or (iv) your breach of these terms and conditions. Mylan shall provide notice to you promptly of any such claim, suit, or proceeding.

    No Advice 
    Nothing contained in Mylan’s Web sites should be construed as medical, legal, investment, financial or other advice. Without limitation, nothing contained in the sites should replace medical advice, medical visits, or recommendations from health care providers.

    Your Conduct 
    You may not alter or attempt to alter the Web site itself. You also may not create a link to the Web site without first obtaining written authorization from Mylan. Further, you may not use the Web site services in any manner that could disable, overburden, or impair any of Mylan’s servers or servers to which Mylan has obtained access, or interfere with any third party’s use and enjoyment of the Web site services, other accounts, computer systems, or networks connected to any Mylan server or the Web site, through hacking, password mining, or any other means. You may not obtain or attempt to obtain any materials or information through any means not intentionally made available through the Web site. Your right to use the Web site services may be further limited by international law, federal law, or the laws and regulations of your particular state or locality.

    You shall use the Web site services for your own personal, non-commercial purposes only. You shall not use the Web site services to (i) post user comments containing spam or otherwise duplicative or unsolicited messages in violation of applicable law; (ii) upload or post infringing, obscene, threatening, libelous, or otherwise unlawful or tortious material, including material harmful to children or which violates a third party’s privacy rights; (iii) upload or post material containing software viruses or other harmful computer codes, files, scripts, agents, or programs; or (iv) solicit, for commercial purposes, any users of the Web site services with respect to their Content, by using any personally 

    Governing Law and Venue 
    These terms and conditions will be governed by and interpreted pursuant to the laws of Pennsylvania, United States of America, notwithstanding any principles of conflicts of law. You specifically consent to personal jurisdiction in Pennsylvania in connection with any dispute between you and Mylan arising out of these terms and conditions or pertaining to the subject matter hereof. The parties to these terms and conditions each agree that the exclusive venue for any dispute between the parties arising out of these terms and conditions or pertaining to the subject matter of these terms and conditions will be in the state and federal courts located within Washington County, Pennsylvania. You and Mylan agree that any cause of action arising out of or related to the Web site must commence within one (1) year after the cause of action accrues. Otherwise, such cause of action is permanently barred.

    © Copyright 2015 Mylan N.V. All rights reserved.

  • Privacy Statement

    Mylan Inc.: Privacy Policy for U.S. Residents

    By using the Sites you agree to the terms of this Privacy Policy.

    The Privacy Policy explains how Mylan may:

    • collect,
    • use and
    • disclose

    information we obtain through the “Sites.” The term “Mylan,” “we,” and “us” includes Mylan Inc. and our affiliates and subsidiaries.

    The “Sites” means collectively any website, mobile application or Internet service under the control of Mylan Inc., whether partial or otherwise, in connection with Mylan’s online presence.

    Personal Information” means information that alone or when in combination with other information may be used to readily identify, contact or locate you, such as: name, address, email address or phone number. We do not consider Personal Information to include information that has been anonymized so that it does not allow a third party to easily identify a specific individual.


    We collect Personal Information when you:

    • use the Sites and
    • communicate with us.

    We also collect information, such as anonymous usage statistics, by using cookies, server logs and other similar technology as you use the Sites.

    Using the Sites We collect information you post through the Sites. For example, we collect information when you apply for a job, respond to surveys, post comments or pictures on our social media pages, request information from us or otherwise interact with us online. The Sites will collect the information you provide in such submissions, including any Personal Information.

    Customer Relations We may collect Personal Information through your communications with our customer relations team.

    Cookies, Automatic Data Collection, and Related Technologies The Sites collect and store information that is generated automatically as you use it, including your preferences and anonymous usage statistics.

    When you visit the Sites, we and our third-party service providers receive and record information on our server logs from your browser, including your IP address, and from cookies and similar technology. Most browsers allow you to block and delete cookies. However, if you do that, the Sites may not work properly.

    By using the Sites, you are authorizing us to gather, parse and retain data related to the provision of the Sites.


    We use Personal Information to:

    • facilitate and improve our services;
    • communicate with you and
    • respond to your request for information (e.g., to provide refill reminders) unless otherwise required by law, regulation or governmental audit.

    We may use Personal Information, in aggregate form, for any purpose, including for marketing purposes.

    Internal and Service-Related Usage We use information, including Personal Information, for internal and service-related purposes and may provide it to third parties to allow us to facilitate the Sites. We may use and retain any data we collect to provide and improve our services.

    Communications We may send email to the email address you provide to us for informational and operational purposes, such as customer service or system maintenance.

    Marketing We may use information, including Personal Information, to provide advertising on the Sites and to facilitate transmittal of information about our products or services we think may be useful or relevant to you. We do not rent, sell or share Personal Information about you with other people or nonaffiliated companies for their direct marketing purposes, unless we have your permission. We may allow access to other data collected by the Sites to enable the delivery of online advertising on the Sites, or otherwise facilitate transmittal of information we think may be useful or relevant to you.

    Aggregate Data We may anonymize and aggregate data collected through the Sites and use it for any purpose.


    We may share your information:

    • with our third-party service providers;
    • to comply with legal obligations;
    • to protect and defend our rights and property and
    • with your permission.

    We do not rent, sell or share Personal Information about you with other people or nonaffiliated companies for their direct marketing purposes, unless we have your permission.

    We Use Vendors and Service Providers may share any information we receive with vendors and service providers retained in connection with the provision of the Sites.

    Social Networking and Other Websites The Sites may allow you to share information, including Personal Information, with social networking websites, such as Facebook. We do not share your Personal Information with them unless you direct the Sites to share it. Their use of the information will be governed by their privacy policies, and you may be able to modify your privacy settings on their websites.

    As Required By Law and Similar Disclosures We may access, preserve and disclose your Personal Information, other account information and content if we believe doing so is required or appropriate to: comply with law enforcement requests and legal process, such as a court order or subpoena; respond to your requests; or protect your, our or others’ rights, property or safety.

    Merger, Sale, or Other Asset Transfers If we are involved in a merger, acquisition, financing due diligence, reorganization, bankruptcy, receivership, sale of Mylan assets or transition of service to another provider, your information may be sold or transferred as part of such a transaction as permitted by law and/or contract. We cannot control how such entities may use or disclose such information.

    We may also disclose your Personal Information with your permission.


    We take steps to ensure that your information is treated securely and in accordance with this Privacy Policy. Unfortunately, the Internet cannot be guaranteed to be 100% secure, and we cannot ensure or warrant the security of any information you provide to us. We do not accept liability for unintentional disclosure.

    By using the Sites or providing Personal Information to us, you agree that we may communicate with you electronically regarding security, privacy and administrative issues relating to your use of the Sites. If we learn of a security system’s breach, we may attempt to notify you electronically by posting a notice on the Sites or sending an email to you. You may have a legal right to receive this notice in writing. To receive free written notice of a security breach (or to withdraw your consent from receiving electronic notice), please notify us at communications@mylan.com.


    We do not knowingly collect information from children under 13 years old.  We will take steps to delete it if we learn we have collected it.

    We do not knowingly collect, maintain or use Personal Information from children under 13 years old, and no part of the Sites is directed to children under the age of 13. If you learn that your child has provided us with Personal Information without your consent, you may alert us at communications@mylan.com. If we learn that we have collected any Personal Information from children under 13 years old, we will promptly take steps to delete such information and terminate the child’s account.


    As a convenience to our visitors, the Sites may contain links to the websites of another company or organization. When you click on one of these links, you will be transferred from our Sites and be connected to the website of the company or organization you selected. Our Privacy Policy does not apply when you leave our Sites.


    By using the Sites, you will transfer data to the United States.

    If you are visiting from the European Union or other regions with laws governing data collection and use, please note that you are agreeing to the transfer of your information to the United States and processing globally. By providing your information you consent to any transfer and processing in accordance with this Privacy Policy.


    If you would like to update or correct any information that you have provided to us through your use of the Sites or otherwise, or if you have suggestions for improving this Privacy Policy, please send an email to communications@mylan.com or write to us at the address below.


    We may revise this Privacy Policy, so review it periodically.

    Posting of Revised Privacy Policy We will post any adjustments to the Privacy Policy on this web page, and the revised version will be effective when it is posted. If you are concerned about how your information is used, bookmark this page and read this Privacy Policy periodically.

    New Uses of Personal Information From time to time, we may desire to use Personal Information for uses not previously disclosed in our Privacy Policy. If our practices change regarding previously collected Personal Information in a way that would be materially less restrictive than stated in the version of this Privacy Policy in effect at the time we collected the information, we will make reasonable efforts to provide notice and obtain consent to any such uses as may be required by law.

    Contact Information

    Mylan Inc.
    Attn: Global Communications
    1000 Mylan Boulevard
    Canonsburg, Pa. 15317

    Effective Date: Dec. 16, 2013

    Last Updated Date: Dec. 16, 2013

You are Leaving Mylan.com

You are arriving at a third-party site that contains content that is not controlled by Mylan.

By clicking "Continue", you acknowledge and agree to the terms and/or the other statements set forth below.


In connection with the proposed acquisition of Meda AB (publ.) (“Meda”) by Mylan N.V. (“Mylan”) (the “Meda Acquisition”) and the related offer by Mylan for the shares of Meda (the “Offer”), you acknowledge the following:

Forward-Looking Statements
The communications on this website contain “forward-looking statements.” Such forward-looking statements may include, without limitation, statements about the Meda Acquisition, the benefits and synergies of the Meda Acquisition, future opportunities for Mylan, Meda, or the combined company and products and any other statements regarding Mylan's, Meda’s or the combined company’s future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as “will,” “may,” “could,” “should,” “would,” “project,” “believe,” “anticipate,” “expect,” “plan,” “estimate,” “forecast,” “potential,” “intend,” “continue,” “target” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties related to the Meda Acquisition, including as to the timing of the Meda Acquisition, uncertainties as to whether Mylan will be able to complete the Meda Acquisition, the possibility that competing offers will be made, the possibility that certain conditions to the completion of the Offer will not be satisfied, and the possibility that Mylan will be unable to obtain regulatory approvals for the Meda Acquisition or be required, as a condition to obtaining regulatory approvals, to accept conditions that could reduce the anticipated benefits of the Meda Acquisition; the ability to meet expectations regarding the accounting and tax treatments of Mylan's acquisition (the "EPD Transaction") of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business (the “EPD Business”) and the Meda Acquisition; changes in relevant tax and other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the integration of the EPD Business and Meda being more difficult, time-consuming, or costly than expected; operating costs, customer loss, and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients, or suppliers) being greater than expected following the EPD Transaction and the Meda Acquisition; the retention of certain key employees of the EPD Business and Meda being difficult; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with the EPD Transaction and the Meda Acquisition within the expected time-frames or at all and to successfully integrate the EPD Business and Meda; expected or targeted future financial and operating performance and results; the capacity to bring new products to market, including but not limited to where Mylan uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); any regulatory, legal, or other impediments to Mylan's ability to bring new products to market; success of clinical trials and Mylan's ability to execute on new product opportunities; any changes in or difficulties with our inventory of, and our ability to manufacture and distribute, the EpiPen® Auto-Injector to meet anticipated demand; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on financial condition, results of operations, and/or cash flows; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan, Meda or the combined company; the inherent challenges, risks, and costs in identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan's business activities, see the risks described in Mylan's Annual Report on Form 10-K for the year ended December 31, 2015, as amended, its Quarterly Report on Form 10-Q for the three months ended March 31, 2016 and its other filings with the SEC. These risks and uncertainties also include those risks and uncertainties that are discussed in the offer document that was submitted to the Swedish Financial Supervisory Authority (“SFSA”) and published on June 16, 2016 upon approval by the SFSA (the “Offer Document”), the Registration Statement on Form S-4 filed with the SEC on April 11, 2016, as amended (as declared effective on June 16, 2016, the “Registration Statement”), and the EU Prospectus that was submitted to the Netherlands Authority for the Financial Markets (“AFM”) and published on June 16, 2016 upon approval by the AFM (the “EU Prospectus”). You can access Mylan's filings with the SEC through the SEC website at www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update any statements herein for revisions or changes after the date of the communications on this website, except as required by law.

Additional Information
In connection with the Offer, the Offer Document was approved by the SFSA and published by Mylan on June 16, 2016. In addition, Mylan has filed certain materials with the SEC, including, among other materials, the Registration Statement, which was declared effective on June 16, 2016. The EU Prospectus was approved by the AFM and published by Mylan on June 16, 2016. The communications on this website are not intended to be, and are not, a substitute for such documents or for any other document that Mylan may file with the SFSA, the SEC, the AFM or any other competent EU authority in connection with the Offer. The communications on this website contain advertising materials (reclame-uitingen) in connection with the Offer as referred to in Section 5:20 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). INVESTORS AND SECURITYHOLDERS OF MEDA IN SWEDEN AND INVESTORS AND SECURITYHOLDERS OF MEDA IN THE EUROPEAN ECONOMIC AREA BUT OUTSIDE OF SWEDEN ARE URGED TO READ THE OFFER DOCUMENT APPROVED BY THE SFSA AND ANY SUPPLEMENT THERETO, OR THE EU PROSPECTUS APPROVED BY THE AFM AND ANY SUPPLEMENT THERETO, AS APPLICABLE, CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, MEDA AND THE OFFER. INVESTORS AND SECURITYHOLDERS OF MEDA OUTSIDE THE EUROPEAN ECONOMIC AREA ARE URGED TO READ ANY DOCUMENTS FILED WITH THE SFSA, THE SEC AND THE AFM OR ANY OTHER COMPETENT EU AUTHORITY CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL EACH CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, MEDA AND THE OFFER. Such documents are or upon publication will be available free of charge through the website maintained by the SEC at www.sec.gov, on Mylan's website at medatransaction.mylan.com or, to the extent filed with the AFM, through the website maintained by the AFM at www.afm.nl, or by directing a request to Mylan at +1 724-514-1813 or investor.relations@mylan.com. Any materials filed by Mylan with the SFSA, the SEC, the AFM or any other competent EU authority that are required to be mailed to Meda shareholders will also be mailed to such shareholders.

Further Information
The Offer is not being made to persons whose participation in the Offer requires that an additional offer document be prepared or registration effected or that any other measures be taken in addition to those required under Swedish law (including the Swedish Takeover Rules), Dutch law, United Kingdom law, Danish law, Irish law and U.S. law.

The distribution of the communications on this website and any related Offer documentation in certain jurisdictions may be restricted or affected by the laws of such jurisdictions. Accordingly, copies of the communications on this website and any related Offer documentation are not being, and must not be, mailed or otherwise forwarded, distributed or sent in, into or from any such jurisdiction. Therefore, persons who receive the communications on this website (including, without limitation, nominees, trustees and custodians) and are subject to the laws of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, Mylan disclaims any responsibility or liability for the violations of any such restrictions by any person.

The Offer is not being made, and the communications on this website may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of such communications or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law (including the Swedish Takeover Rules), Dutch law, United Kingdom law, Danish law, Irish law and U.S. law.

Non-GAAP financial measures
This website contains non-GAAP financial measures. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with GAAP.

Special notice to shareholders in the United States
This Offer is made for the securities of a foreign company. The Offer is subject to disclosure requirements of a foreign country that are different from those of the United States. Certain financial statements included or incorporated by reference in the Offer documents, have been prepared in accordance with foreign accounting standards that may not be comparable to the financial statements of U.S. companies.

It may be difficult for investors to enforce their rights and any claim they may have arising under the federal securities laws, since Meda is incorporated in Sweden and Mylan is incorporated in the Netherlands, and some or all of their respective officers and directors may be residents of a foreign country. Investors may not be able to sue a foreign company or its officers or directors in a foreign court for violations of the U.S. securities laws. It may be difficult to compel a foreign company and its affiliates to subject themselves to a U.S. court’s judgment.

Investors should be aware that Mylan may purchase securities otherwise than under the Offer, such as in open market or privately negotiated purchases.


I samband med det föreslagna förvärvet av Meda AB (publ.) (”Meda”) att genomföras av Mylan N.V. (”Mylan”) (”Förvärvet av Meda”) och det i samband därmed av Mylan lämnade uppköpserbjudandet avseende aktierna i Meda (”Erbjudandet”), bekräftar du härmed följande:

Framåtriktad information
Informationen på denna webbplats innehåller ”framåtriktad information”. Sådan framåtriktad information kan innehålla, men är inte begränsad till, information om Förvärvet av Meda, fördelarna och synergier med Förvärvet av Meda, framtida möjligheter för Mylan, Meda eller det sammanslagna bolaget samt produkter och annan information avseende Mylans, Medas eller det sammanslagna bolagets framtida verksamhet, förväntade affärsnivåer, förväntade lönsamhet, planerade åtgärder, förväntade tillväxt, marknadsmöjligheter, strategier, konkurrens, samt andra förväntningar och målsättningar för framtida perioder. Sådan information kan ofta kännas igen då den innehåller uttryck som ”kommer”, ”kan”, ”skulle”, ”bör”, ”ska”, ”bedömer”, ”tror”, ”förutser”, ”förväntar”, ”planerar”, ”uppskattar”, ”prognostiserar”, ”potentiell”, ”avser”, ”fortsätter”, ”mål” samt liknande uttryck eller jämförbara ord. Eftersom framåtblickande uttalanden i sig innebär risker och osäkerheter kan de faktiska framtida resultaten avvika väsentligt från dem som uttrycks eller antyds i sådana framtidsinriktade uttalanden. Faktorer som kan orsaka eller bidra till sådana avvikelser är, men är inte begränsade till: osäkerheter relaterade till Förvärvet av Meda, inklusive timingen av Förvärvet av Meda, osäkerheter avseende om Mylan kommer kunna fullfölja Förvärvet av Meda, möjligheten att någon lämnar ett konkurrerande erbjudande, möjligheten att vissa av villkoren för fullföljande av Erbjudandet inte uppfylls, samt möjligheten att Mylan inte kommer att erhålla erforderliga myndighetsgodkännanden för Förvärvet av Meda eller vara tvungna, för att erhålla myndighetsgodkännanden, att acceptera villkor som kan reducera de förväntade fördelarna med Förvärvet av Meda; förmågan att möta förväntningarna avseende hantering av redovisning och skatt för Mylans förvärv (”EPD-transaktionen”) av Mylan Inc. och Abbott Laboratories verksamhet för specialistläkemedel och generiska läkemedel under eget namn på välutvecklade marknader utanför USA (”EPD-verksamheten”) och Förvärvet av Meda; förändringar i skattelagstiftning eller annan lagstiftning, inklusive men inte begränsat till förändringar av den amerikanska skattelagstiftningen, vård- och läkemedelslagstiftning och bestämmelser i USA och utomlands; integrationen av EPD-verksamheten och Meda blir svårare, mer tidskrävande eller kostsam än förväntat; operativa kostnader, förlust av kunder, samt störningar i verksamheten (inklusive, men inte begränsat till, svårigheter att bibehålla medarbetare, kunder, klienter eller underleverantörer) blir större än förväntat efter EPD-transaktionen och Förvärvet av Meda; svårigheter med att behålla vissa nyckelpersoner i EPD-verksamheten och Meda; möjligheten att Mylan inte kan uppnå förväntade synergier och effektiviseringar i verksamheten i samband med EPD-transaktionen och Förvärvet av Meda inom den förväntade tidsramen eller att alls lyckas med att integrera EPD-verksamheten och Meda; förväntade eller mål för framtida finansiella och operativa prestationer och resultat; förmågan att introducera nya produkter till marknaden, inklusive men inte begränsat till när Mylan gör affärsmässiga bedömningar och beslutar att tillverka, marknadsföra och/eller sälja produkter, direkt eller genom tredje part, trots att invändningar om patentintrång inte slutligen har avgjorts av domstol (d.v.s. en ”at-risk launch”); eventuella regulatoriska, legala eller andra hinder för Mylans möjlighet att introducera nya produkter på marknaden; framgång i kliniska studier och Mylans förmåga att agera på nya produktmöjligheter; omfattningen, timingen, samt slutresultatet av eventuella pågående rättsliga förfaranden och sådana förfarandens påverkan på finansiell ställning, resultat av verksamheten och/eller kassaflöde; förmågan att skydda immateriella rättigheter och försvara dessa rättigheter; effekten av eventuella förändringar vad gäller förhållandet till kunder och underleverantörer och kunders köpmönster; förmågan att attrahera och bibehålla nyckelpersoner; ändringar i relationen till tredje part; påverkan av konkurrens; förändringar i ekonomiska och finansiella förutsättningar för verksamheten i Mylan, Meda eller det sammanslagna bolaget; de inneboende utmaningarna, kostnaderna och riskerna med att identifiera, förvärva och integrera komplementerande eller strategiska förvärv av andra företag, produkter eller tillgångar och i att uppnå de förväntade synergierna; osäkerheter och händelser utanför ledningens kontroll; och inneboende osäkerheter med estimat och bedömningar använda vid framställningen av finansiella rapporter, och tillhandahållandet av estimat och finansiella mått, i enlighet med allmänt accepterade redovisningsprinciper i USA och tillhörande standarder eller på en justerad grund. För mer detaljerad information om riskerna och osäkerheterna förenade med Mylans verksamhet, se riskerna beskrivna i Mylans årsredovisning på Form 10-K för året som avslutades 31 december 2015, i gällande version, Mylans delårsrapport på Form 10 Q för de tre månader som avslutades 31 mars 2016, samt andra inlämnade dokument hos SEC. Dessa risker och osäkerheter inkluderar även de risker och osäkerheter som diskuteras i erbjudandehandlingen som lämnats in till Finansinspektionen och som offentliggjordes den 16 juni 2016 efter att den godkänts av Finansinspektionen (”Erbjudandehandlingen”), Registration Statement på Form S-4 som lämnats in till SEC den 11 april 2016, i gällande version (som gavs effekt den 16 juni 2016, ”Registration Statement”) samt EU-prospektet som lämnats in till nederländska Authority for the Financial Markets (”AFM”) och som offentliggjordes den 16 juni 2016 efter att den godkänts av AFM (”EU-prospektet”). Åtkomst till Mylans inlämnade dokument hos SEC är möjlig via SEC:s webbplats www.sec.gov, och Mylan rekommenderar starkt alla att läsa dessa. Förutom vad som krävs enligt tillämplig lag, åtar sig inte Mylan någon skyldighet att uppdatera uttalanden häri för revideringar eller ändringar efter dagen för offentliggörandet på denna webbplats.

I samband med Erbjudandet godkändes Erbjudandehandlingen av Finansinspektionen och offentliggjordes av Mylan den 16 juni 2016. Därutöver har Mylan lämnat in vissa handlingar till SEC, inklusive bland annat Registration Statement, vilken gavs effekt den 16 juni 2016. EU-prospektet godkändes av AFM och offentliggjordes av Mylan den 16 juni 2016. Informationen på denna webbplats är inte avsedd att vara och utgör inte ett substitut för sådana dokument eller för eventuella andra dokument som Mylan kan komma att lämna in till Finansinspektionen, SEC, AFM eller någon annan behörig myndighet inom EU i samband med Erbjudandet. Informationen på denna webbplats innehåller marknadsföringsmaterial (reclame-uitingen) hänförligt till Erbjudandet så som framgår av paragraf 5:20 i nederländska Financial Supervision Act (Wet op het financieel toezicht). INVESTERARE OCH VÄRDEPAPPERSINNEHAVARE I MEDA INOM SVERIGE SAMT INVESTERARE OCH VÄRDEPAPPERSINNEHAVARE INOM EUROPEISKA EKONOMISKA SAMMARBETSOMRÅDET MEN UTANFÖR SVERIGE UPPMANAS ATT NOGGRANT OCH I HELHET LÄSA DEN ERBJUDANDEHANDLING SOM ÄR GODKÄND AV FINANSINSPEKTIONEN SAMT EVENTUELLA TILLÄGG DÄRTILL, ELLER, BEROENDE PÅ VAD SOM ÄR TILLÄMPLIGT, DET EU-PROSPEKT SOM ÄR GODKÄNT AV AFM SAMT EVENTUELLA TILLÄGG DÄRTILL, INNAN ETT INVESTERINGSBESLUT FATTAS EFTERSOM DE KOMMER ATT INNEHÅLLA VIKTIG INFORMATION OM MYLAN, MEDA OCH ERBJUDANDET. INVESTERARE OCH VÄRDEPAPPERSINNEHAVARE I MEDA UTANFÖR DET EUROPEISKA EKONOMISKA SAMMARBETSOMRÅDET UPPMANAS ATT NOGGRANT OCH I HELHET LÄSA ALLA DOKUMENT INLÄMNADE TILL FINANSINSPEKTIONEN, SEC OCH AFM ELLER NÅGON ANNAN BEHÖRIG MYNDIGHET INOM EU INNAN ETT INVESTERINGSBESLUT FATTAS EFTERSOM DE VAR FÖR SIG KOMMER ATT INNEHÅLLA VIKTIG INFORMATION OM MYLAN, MEDA OCH ERBJUDANDET. Sådana dokument kommer att när de offentliggjorts finnas fritt tillgängliga via den webbplats som tillhandahålls av SEC www.sec.gov, på Mylans webbplats medatransaction.mylan.com eller, för vad som lämnas in till AFM, via den webbplats som tillhandahålls av AFM www.afm.nl, eller genom en direkt förfrågan till Mylan på + 1 724-514-1813 eller investor.relations@mylan.com. Eventuellt material inlämnat av Mylan till Finansinspektionen, SEC, AFM eller någon annan behörig myndighet inom EU och som behöver skickas till aktieägare i Meda kommer också att skickas till sådana aktieägare.

Ytterligare information
Erbjudandet lämnas inte till personer vars deltagande i Erbjudandet kräver att ytterligare erbjudandehandlingar upprättas eller registrering sker eller att någon annan åtgärd vidtas utöver vad som krävs enligt svensk lag (inklusive takeover-reglerna), nederländsk lag, lagen i Storbritannien, dansk lag, irländsk lag och amerikansk lag.

Distribution av informationen på denna webbplats och andra dokument hänförliga till Erbjudandet kan i vissa jurisdiktioner vara föremål för restriktioner eller påverkas av lagar i sådana jurisdiktioner. Exemplar av informationen på denna webbplats och andra dokument hänförliga till Erbjudandet skickas således inte, och får inte skickas, eller på annat sätt vidarebefordras, distribueras eller sändas, inom, in i eller från någon sådan jurisdiktion. Därför måste personer som mottar informationen på denna webbplats (inklusive, men inte begränsat till, förvaltare, förmyndare och panthavare) och som är underkastade lagarna i en sådan jurisdiktion, informera sig om, och iaktta, eventuella tillämpliga lagar och regler. Underlåtenhet att göra detta kan utgöra en överträdelse av värdepapperslagar i en sådan jurisdiktion. Mylan avsäger sig, i den mån det är möjligt enligt tillämplig lag, allt ansvar för personers eventuella överträdelser av sådana bestämmelser.

Erbjudandet lämnas inte, och information på denna webbplats får inte distribueras, vare sig direkt eller indirekt, i eller till, och inga anmälningssedlar kommer att accepteras från eller på uppdrag av aktieägare i Australien, Hongkong, Japan, Kanada, Nya Zeeland, Sydafrika eller något annat land där Erbjudandet, distribution av sådan information eller godkännande av accept av Erbjudandet skulle strida mot tillämpliga lagar eller regler eller skulle kräva att ytterligare erbjudandehandlingar upprättas eller registrering sker eller att någon annan åtgärd vidtas utöver vad som krävs enligt svensk lag (inklusive takeover-reglerna), nederländsk lag, lagen i Storbritannien, dansk lag, irländsk lag och amerikansk lag.

Finansiella nyckeltal som inte upprättats i enlighet med US GAAP
Denna webbplats innehåller finansiella nyckeltal som inte är upprättade i enlighet med US GAAP. Finansiella nyckeltal som inte är upprättade i enlighet med US GAAP ska endast ses som ett komplement till, och inte som en ersättning för eller som ett överordnat nyckeltal i förhållande till, finansiella nyckeltal upprättade i enlighet med US GAAP.

Meddelande till aktieägare i USA
Erbjudandet avser värdepapper i ett icke-amerikanskt bolag. Erbjudandet är föremål för regler om offentliggörande av information under ett icke-amerikanskt lands lagar, vilka skiljer sig från motsvarande regler i USA. Viss finansiell informationen i, eller införlivad genom hänvisning i, dokument hänförliga till Erbjudandet har upprättats i enlighet med utländsk redovisningssed och är inte jämförbar med motsvarande finansiell information för amerikanska bolag.

Eftersom Meda har sitt säte i Sverige och Mylan har sitt säte i Nederländerna och samtliga eller vissa av deras styrelseledamöter eller företrädare kan ha hemvist utanför USA kan det vara förenat med svårigheter för aktieägare att göra gällande rättigheter och krav enligt federal värdepapperslagstiftning. Det är inte säkert att investerare kan stämma ett icke-amerikanskt bolag eller dess styrelseledamöter eller företrädare i en domstol utanför USA för överträdelser av amerikansk värdepapperslagstiftning. Det kan vara förenat med svårigheter att tvinga ett icke-amerikanskt bolag eller dess dotterbolag att rätta sig efter ett amerikanskt domslut.

Investerare uppmärksammas på att Mylan kan komma att förvärva aktier på annat sätt än genom Erbjudandet. Sådana förvärv kan antingen ske på den öppna marknaden till rådande aktiekurs eller genom privata sidoaffärer till framförhandlat pris.